From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:2fvd.gif|left|200px]] | + | {{Seed}} |
| | + | [[Image:2fvd.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_2fvd| PDB=2fvd | SCENE= }} | | {{STRUCTURE_2fvd| PDB=2fvd | SCENE= }} |
| | | | |
| - | '''Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitor'''
| + | ===Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitor=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | The cyclin-dependent kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. Since deregulation of CDKs is found with high frequency in many human cancer cells, pharmacological inhibition of CDKs with small molecules has the potential to provide an effective strategy for the treatment of cancer. The 2,4-diamino-5-ketopyrimidines 6 reported here represent a novel class of potent and ATP-competitive inhibitors that selectively target the cyclin-dependent kinase family. This diaminopyrimidine core with a substituted 4-piperidine moiety on the C2-amino position and 2-methoxybenzoyl at the C5 position has been identified as the critical structure responsible for the CDK inhibitory activity. Further optimization has led to a good number of analogues that show potent inhibitory activities against CDK1, CDK2, and CDK4 but are inactive against a large panel of serine/threonine and tyrosine kinases (K(i) > 10 microM). As one of these representative analogues, compound 39 (R547) has the best CDK inhibitory activities (K(i) = 0.001, 0.003, and 0.001 microM for CDK1, CDK2, and CDK4, respectively) and excellent in vitro cellular potency, inhibiting the growth of various human tumor cell lines including an HCT116 cell line (IC(50) = 0.08 microM). An X-ray crystal structure of 39 bound to CDK2 has been determined in this study, revealing a binding mode that is consistent with our SAR. Compound 39 demonstrates significant in vivo efficacy in the HCT116 human colorectal tumor xenograft model in nude mice with up to 95% tumor growth inhibition. On the basis of its superior overall profile, 39 was chosen for further evaluation and has progressed into Phase I clinical trial for the treatment of cancer. | + | The line below this paragraph, {{ABSTRACT_PUBMED_17064073}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 17064073 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_17064073}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 27: |
Line 31: |
| | [[Category: Lukacs, C M.]] | | [[Category: Lukacs, C M.]] |
| | [[Category: Cdk2 ligand]] | | [[Category: Cdk2 ligand]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 04:20:51 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 11:53:19 2008'' |
Revision as of 08:53, 29 July 2008
Template:STRUCTURE 2fvd
Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitor
Template:ABSTRACT PUBMED 17064073
About this Structure
2FVD is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-diflu oro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity., Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer P, Yin X, Smith MA, Higgins BX, Chen Y, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N, J Med Chem. 2006 Nov 2;49(22):6549-60. PMID:17064073
Page seeded by OCA on Tue Jul 29 11:53:19 2008
